These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 10589371)

  • 21. The use of antimicrobial peptides in ophthalmology: an experimental study in corneal preservation and the management of bacterial keratitis.
    Mannis MJ
    Trans Am Ophthalmol Soc; 2002; 100():243-71. PubMed ID: 12545697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.
    Williamson DA; Carter GP; Howden BP
    Clin Microbiol Rev; 2017 Jul; 30(3):827-860. PubMed ID: 28592405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial keratitis.
    Kaye S; Tuft S; Neal T; Tole D; Leeming J; Figueiredo F; Armstrong M; McDonnell P; Tullo A; Parry C
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):362-8. PubMed ID: 19684005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
    Romanowski EG; Mah FS; Yates KA; Kowalski RP; Gordon YJ
    Am J Ophthalmol; 2005 May; 139(5):867-77. PubMed ID: 15860293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topical antimicrobial agents and antibiotics for the eye.
    McCloskey RV
    Med Clin North Am; 1988 May; 72(3):717-22. PubMed ID: 3280915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Besifloxacin in the management of bacterial infections of the ocular surface.
    Deschênes J; Blondeau J
    Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimicrobial drug delivery to the eye.
    Lesar TS; Fiscella RG
    Drug Intell Clin Pharm; 1985 Sep; 19(9):642-54. PubMed ID: 3899562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations of current antibiotics for the treatment of bacterial conjunctivitis.
    Karpecki P; Paterno MR; Comstock TL
    Optom Vis Sci; 2010 Nov; 87(11):908-19. PubMed ID: 20838353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
    Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC
    Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical fluoroquinolones for eye and ear.
    Morden NE; Berke EM
    Am Fam Physician; 2000 Oct; 62(8):1870-6. PubMed ID: 11057842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW; Ward KW
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.
    Ghelardi E; Tavanti A; Davini P; Celandroni F; Salvetti S; Parisio E; Boldrini E; Senesi S; Campa M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3396-401. PubMed ID: 15328102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH; Fung HB
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bioavailability of antibiotics].
    Robert PY; Tassy A
    J Fr Ophtalmol; 2000 May; 23(5):510-3; quiz 523. PubMed ID: 10844315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones.
    McDonald M; Blondeau JM
    J Cataract Refract Surg; 2010 Sep; 36(9):1588-98. PubMed ID: 20692574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current therapy for bacterial keratitis and bacterial conjunctivitis.
    Steinert RF
    Am J Ophthalmol; 1991 Oct; 112(4 Suppl):10S-14S. PubMed ID: 1928267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chlorhexidine gluconate 0.02% as adjunct to primary treatment for corneal bacterial ulcers.
    Geffen N; Norman G; Kheradiya NS; Assia EI
    Isr Med Assoc J; 2009 Nov; 11(11):664-8. PubMed ID: 20108552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Topical antibiotics in skin infections].
    Thaçi D; Schöfer H
    Hautarzt; 2005 Apr; 56(4):381-94; quiz 395. PubMed ID: 15765214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review: Emerging strategies for antimicrobial drug delivery to the ocular surface: Implications for infectious keratitis.
    Sharma A; Taniguchi J
    Ocul Surf; 2017 Oct; 15(4):670-679. PubMed ID: 28602948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
    Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
    J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.